Vedolizumab (Entyvio) is recommended. It is a possible option for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor (TNF)‑alpha inhibitor isn’t suitable or hasn’t worked well enough.
People should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have it. If they no longer have symptoms, treatment can be stopped, and later restarted if symptoms return.
People who continue to take vedolizumab should be assessed at least every 12 months to see whether the treatment is working well enough for them to carry on taking it.
What does this mean for me?
If you have moderate to severe Crohn’s disease, and your doctor thinks that vedolizumab is the right treatment, you should be able to have the treatment on the NHS.
Vedolizumab should be available on the NHS within 3 months of the guidance being issued.
If you are not eligible for treatment as described above, you should be able to continue taking vedolizumab until you and your doctor decide it is the right time to stop.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.